+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pyelonephritis - Pipeline Review, H2 2019

  • ID: 4866522
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 122 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Achaogen Inc
  • Allecra Therapeutics GmbH
  • AlloVir Inc
  • Entasis Therapeutics Inc
  • Iterum Therapeutics Plc
  • Meiji Seika Pharma Co Ltd
  • MORE
Pyelonephritis - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides an overview of the Pyelonephritis (Infectious Disease) pipeline landscape.

Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in urethra or bladder and travels up into kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion and back pain or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract and damage to nerves around the bladder. Treatment includes antibiotics.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Pyelonephritis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Pyelonephritis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pyelonephritis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 5, 6, 1 and 2 respectively.

Pyelonephritis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pyelonephritis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pyelonephritis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pyelonephritis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pyelonephritis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pyelonephritis (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pyelonephritis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pyelonephritis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Achaogen Inc
  • Allecra Therapeutics GmbH
  • AlloVir Inc
  • Entasis Therapeutics Inc
  • Iterum Therapeutics Plc
  • Meiji Seika Pharma Co Ltd
  • MORE
Introduction
Report Coverage
Pyelonephritis - Overview
Pyelonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pyelonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pyelonephritis - Companies Involved in Therapeutics Development
Achaogen Inc
Allecra Therapeutics GmbH
AlloVir Inc
Entasis Therapeutics Inc
Iterum Therapeutics Plc
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics Inc
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
Paratek Pharmaceuticals Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
XuanZhu Pharma Co Ltd
Pyelonephritis - Drug Profiles
(AAI-101 + cefepime) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(cefepime + VNRX-5133) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(ceftolozane sulfate + tazobactam sodium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(durlobactam sodium + sulbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(meropenem + vaborbactam) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALVR-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benapenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceforanide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
finafloxacin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfomycin disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nacubactam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plazomicin sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sulopenem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tebipenem pivoxil hydrobromide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pyelonephritis - Dormant Projects
Pyelonephritis - Discontinued Products
Pyelonephritis - Product Development Milestones
Featured News & Press Releases
Sep 03, 2019: Allecra Therapeutics to present data at ASM/ESCMID 2019 Conference on drug development to meet the challenge of antimicrobial resistance
Jul 29, 2019: Merck receives positive EU CHMP opinion for ZERBAXA 3g dose (ceftolozane and tazobactam) for the treatment of adults with Hospital-Acquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP)
Apr 15, 2019: Paratek Pharmaceuticals broadens clinical profile of NUZYRA (Omadacycline) with New ECCMID 2019 Data Presentations
Apr 10, 2019: Entasis Therapeutics announces presentations on ETX2514SUL at ECCMID 2019
Mar 29, 2019: Spero Therapeutics receives FDA fast track designation for SPR994 for the treatment of complicated urinary tract infections and acute pyelonephritis
Feb 21, 2019: Achaogen announces ZEMDRI (plazomicin) pivotal phase 3 study results published in the New England Journal of Medicine
Feb 14, 2019: Achaogen submits response to ASPR/BARDA request for information (RFI) for antimicrobial resistance project BioShield
Dec 11, 2018: The Menarini Group announces Meropenem/vaborbactam European marketing authorization
Nov 27, 2018: Paratek Pharmaceuticals doses first patient in phase 2 clinical trial of Omadacycline in acute pyelonephritis, a common subset of complicated urinary tract infections
Oct 17, 2018: Achaogen submits marketing authorization application to the European Medicines Agency for Plazomicin
Oct 03, 2018: Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018
Sep 19, 2018: Achaogen announces multiple Plazomicin presentations at IDWeek 2018
Sep 04, 2018: Achaogen highlights multiple Plazomicin presentations at ESCMID/ASM 2018 Conference
Aug 14, 2018: Entasis Therapeutics announces positive topline results from phase 2 trial of ETX2514SUL in patients with complicated urinary tract infections including acute pyelonephritis
Aug 03, 2018: CMS grants new technology add-on payment to ZEMDRI (plazomicin)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Pyelonephritis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Products under Development by Companies, H2 2019
Table 4: Number of Products by Stage and Target, H2 2019
Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
Table 6: Number of Products by Stage and Route of Administration, H2 2019
Table 7: Number of Products by Stage and Molecule Type, H2 2019
Table 8: Pyelonephritis - Pipeline by Achaogen Inc, H2 2019
Table 9: Pyelonephritis - Pipeline by Allecra Therapeutics GmbH, H2 2019
Table 10: Pyelonephritis - Pipeline by AlloVir Inc, H2 2019
Table 11: Pyelonephritis - Pipeline by Entasis Therapeutics Inc, H2 2019
Table 12: Pyelonephritis - Pipeline by Iterum Therapeutics Plc, H2 2019
Table 13: Pyelonephritis - Pipeline by Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd, H2 2019
Table 14: Pyelonephritis - Pipeline by Meiji Seika Pharma Co Ltd, H2 2019
Table 15: Pyelonephritis - Pipeline by Melinta Therapeutics Inc, H2 2019
Table 16: Pyelonephritis - Pipeline by Merck & Co Inc, H2 2019
Table 17: Pyelonephritis - Pipeline by MerLion Pharmaceuticals Pte Ltd, H2 2019
Table 18: Pyelonephritis - Pipeline by Nabriva Therapeutics Plc, H2 2019
Table 19: Pyelonephritis - Pipeline by Paratek Pharmaceuticals Inc, H2 2019
Table 20: Pyelonephritis - Pipeline by VenatoRx Pharmaceuticals Inc, H2 2019
Table 21: Pyelonephritis - Pipeline by Wockhardt Ltd, H2 2019
Table 22: Pyelonephritis - Pipeline by XuanZhu Pharma Co Ltd, H2 2019
Table 23: Pyelonephritis - Dormant Projects, H2 2019
Table 24: Pyelonephritis - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Pyelonephritis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products by Top 10 Targets, H2 2019
Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Routes of Administration, H2 2019
Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Molecule Types, H2 2019
Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Achaogen Inc
  • Allecra Therapeutics GmbH
  • AlloVir Inc
  • Entasis Therapeutics Inc
  • Iterum Therapeutics Plc
  • Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Melinta Therapeutics Inc
  • Merck & Co Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc
  • VenatoRx Pharmaceuticals Inc
  • Wockhardt Ltd
  • XuanZhu Pharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll